Received September 4, 2007
Accepted on February 2, 2008

BASIC RESEARCH

Downregulation of Hepatic Acetylation of Drugs in Chronic Renal Failure

Emilie Simard ^*, Judith Naud ^*, Josée Michaud ^*, Francois A. Leblond ^*, Alain Bonnardeaux ^*, Chantal Guillemette , Edith Sim , and Vincent Pichette ^*1

Service de néphrologie et Centre de recherche de l’Hôpital Maisonneuve-Rosemont and Département de pharmacologie, Université de Montréal, Montréal, and Faculté de pharmacie, Université Laval, Laval, Québec, Canada; and Department of Pharmacology, University of Oxford, Oxford, United Kingdom

¹ To whom correspondence should be addressed. E-mail: vpichette.hmr{at}ssss.gouv.qc.ca.

	Abstract

Drug metabolism can be affected by chronic renal failure (CRF). Although it is known that several drugs that are known to be acetylated accumulate in CRF, the effect of CRF on N-acetyltransferase (NAT), the enzyme responsible for this acetylation, is unknown. Herein is reported that protein and gene expression of both Nat isoforms in the liver was reduced by >30% and Nat2 activity was reduced by 50% in rats with CRF compared with control rats. Incubation of hepatocytes with serum from rats with CRF suggested that a circulating factor is responsible for the decrease in protein and gene expression. For testing the hypothesis that parathyroid hormone may be this factor, CRF was induced in parathyroidectomized rats; downregulation of Nat expression and activity was not observed in these rats. Furthermore, addition of parathyroid hormone to cultured hepatocytes induced a decrease in Nat2 protein and gene expression. In conclusion, liver acetylation of drugs in a rat model of CRF is reduced by a downregulation of Nat1 and Nat2 isoforms, secondary to decreased gene expression. Parathyroid hormone seems to be an important mediator of this phenomenon.